Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 14.22 Million GBP | -39.56% |
| 2022 | 23.52 Million GBP | -47.29% |
| 2021 | 44.63 Million GBP | -49.59% |
| 2020 | 88.54 Million GBP | 2075.09% |
| 2019 | 4.07 Million GBP | -40.17% |
| 2018 | 6.8 Million GBP | -11.2% |
| 2017 | 7.66 Million GBP | 38.18% |
| 2016 | 5.54 Million GBP | -33.06% |
| 2015 | 8.28 Million GBP | -16.59% |
| 2014 | 9.93 Million GBP | 387.77% |
| 2013 | 2.03 Million GBP | -46.52% |
| 2012 | 3.8 Million GBP | -35.65% |
| 2011 | 5.91 Million GBP | -2.87% |
| 2010 | 6.09 Million GBP | -29.71% |
| 2009 | 8.66 Million GBP | 81.6% |
| 2008 | 4.77 Million GBP | -29.05% |
| 2007 | 6.72 Million GBP | -17.79% |
| 2006 | 8.18 Million GBP | -11.44% |
| 2005 | 9.23 Million GBP | 1359.4% |
| 2004 | 633 Thousand GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 14.22 Million GBP | 0.0% |
| 2023 Q1 | 18.7 Million GBP | -20.5% |
| 2023 FY | 14.22 Million GBP | -39.56% |
| 2023 Q3 | 14.22 Million GBP | -23.98% |
| 2023 Q2 | 18.7 Million GBP | 0.0% |
| 2022 Q3 | 23.52 Million GBP | -20.36% |
| 2022 Q2 | 29.54 Million GBP | 0.0% |
| 2022 FY | 23.52 Million GBP | -47.29% |
| 2022 Q1 | 29.54 Million GBP | -33.81% |
| 2022 Q4 | 23.52 Million GBP | 0.0% |
| 2021 Q3 | 44.63 Million GBP | -22.18% |
| 2021 Q2 | 57.36 Million GBP | 0.0% |
| 2021 FY | 44.63 Million GBP | -49.59% |
| 2021 Q1 | 57.36 Million GBP | -35.22% |
| 2021 Q4 | 44.63 Million GBP | 0.0% |
| 2020 FY | 88.54 Million GBP | 2075.09% |
| 2020 Q1 | 13.76 Million GBP | 238.05% |
| 2020 Q2 | 13.76 Million GBP | 0.0% |
| 2020 Q4 | 88.54 Million GBP | 0.0% |
| 2020 Q3 | 88.54 Million GBP | 543.42% |
| 2019 Q1 | 5.29 Million GBP | -22.24% |
| 2019 Q3 | 4.07 Million GBP | -23.06% |
| 2019 Q4 | 4.07 Million GBP | 0.0% |
| 2019 FY | 4.07 Million GBP | -40.17% |
| 2019 Q2 | 5.29 Million GBP | 0.0% |
| 2018 Q1 | 6.01 Million GBP | -21.52% |
| 2018 FY | 6.8 Million GBP | -11.2% |
| 2018 Q4 | 6.8 Million GBP | 0.0% |
| 2018 Q3 | 6.8 Million GBP | 13.15% |
| 2018 Q2 | 6.01 Million GBP | 0.0% |
| 2017 Q1 | 4.13 Million GBP | -25.39% |
| 2017 Q4 | 7.66 Million GBP | 0.0% |
| 2017 FY | 7.66 Million GBP | 38.18% |
| 2017 Q3 | 7.66 Million GBP | 85.21% |
| 2017 Q2 | 4.13 Million GBP | 0.0% |
| 2016 Q1 | 6.77 Million GBP | -18.25% |
| 2016 FY | 5.54 Million GBP | -33.06% |
| 2016 Q4 | 5.54 Million GBP | 0.0% |
| 2016 Q3 | 5.54 Million GBP | -18.11% |
| 2016 Q2 | 6.77 Million GBP | 0.0% |
| 2015 Q4 | 8.28 Million GBP | 0.0% |
| 2015 Q2 | 9.1 Million GBP | 0.0% |
| 2015 Q1 | 9.1 Million GBP | -8.34% |
| 2015 Q3 | 8.28 Million GBP | -9.01% |
| 2015 FY | 8.28 Million GBP | -16.59% |
| 2014 Q3 | 9.93 Million GBP | 54.57% |
| 2014 Q4 | 9.93 Million GBP | 0.0% |
| 2014 Q2 | 6.42 Million GBP | 0.0% |
| 2014 Q1 | 6.42 Million GBP | 215.57% |
| 2014 FY | 9.93 Million GBP | 387.77% |
| 2013 Q4 | 2.03 Million GBP | 0.0% |
| 2013 Q2 | 2.91 Million GBP | 0.0% |
| 2013 FY | 2.03 Million GBP | -46.52% |
| 2013 Q1 | 2.91 Million GBP | -23.48% |
| 2013 Q3 | 2.03 Million GBP | -30.11% |
| 2012 Q4 | 3.8 Million GBP | 0.0% |
| 2012 Q2 | 2.76 Million GBP | 0.0% |
| 2012 FY | 3.8 Million GBP | -35.65% |
| 2011 FY | 5.91 Million GBP | -2.87% |
| 2011 Q2 | 5.91 Million GBP | 0.0% |
| 2010 Q2 | 6.09 Million GBP | 0.0% |
| 2010 Q4 | 4.84 Million GBP | 0.0% |
| 2010 FY | 6.09 Million GBP | -29.71% |
| 2009 Q2 | 8.66 Million GBP | 0.0% |
| 2009 Q4 | 7.56 Million GBP | 0.0% |
| 2009 FY | 8.66 Million GBP | 81.6% |
| 2008 Q4 | 3.65 Million GBP | 0.0% |
| 2008 Q2 | 4.77 Million GBP | 0.0% |
| 2008 FY | 4.77 Million GBP | -29.05% |
| 2007 Q2 | 6.72 Million GBP | 0.0% |
| 2007 Q4 | 5.76 Million GBP | 0.0% |
| 2007 FY | 6.72 Million GBP | -17.79% |
| 2006 Q4 | 7.49 Million GBP | 0.0% |
| 2006 FY | 8.18 Million GBP | -11.44% |
| 2006 Q2 | 8.18 Million GBP | 0.0% |
| 2005 Q4 | 8.72 Million GBP | 0.0% |
| 2005 FY | 9.23 Million GBP | 1359.4% |
| 2005 Q2 | 9.23 Million GBP | 0.0% |
| 2004 Q2 | 633 Thousand GBP | 0.0% |
| 2004 Q4 | 9.39 Million GBP | 0.0% |
| 2004 FY | 633 Thousand GBP | 0.0% |
| 2003 Q4 | 594 Thousand GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 63.392% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -96.973% |
| SQZ Biotechnologies Company | 107.18 Million USD | 86.733% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -34.745% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 89.078% |
| Mesoblast Limited | 667.9 Million USD | 97.871% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -19551.765% |
| Genus plc | 1.02 Billion USD | 98.618% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -946.93% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2749.677% |
| Marizyme, Inc. | 22.01 Million USD | 35.403% |
| ContraFect Corporation | 20.67 Million USD | 31.23% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -2168.102% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -3542.991% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -3621.051% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -893.064% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -243.003% |
| MultiCell Technologies, Inc. | 126.22 USD | -11266735.684% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1413.373% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 88.934% |
| EV Biologics, Inc. | 431.71 Thousand USD | -3194.079% |
| Q BioMed Inc. | 3.51 Million USD | -304.521% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 59.575% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1745.34% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -5342.882% |
| Biomind Labs Inc. | 73.81 Thousand USD | -19164.688% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 96.928% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 52.62% |
| Skye Bioscience, Inc. | 11.94 Million USD | -19.1% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -329.247% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -417.817% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -626.232% |
| IMV Inc. | 31.33 Million USD | 54.614% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1968.551% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -446.29% |
| GB Sciences, Inc. | 103.44 Thousand USD | -13647.801% |
| Alpha Cognition Inc. | 2.45 Million USD | -479.935% |
| HST Global, Inc. | 1526.00 USD | -931813.499% |
| CSL Limited | 38.02 Billion USD | 99.963% |
| Halberd Corporation | 10.13 Thousand USD | -140271.138% |
| Enzolytics Inc. | 361.7 Million USD | 96.068% |
| Resverlogix Corp. | 8.11 Million USD | -75.243% |
| Affymax, Inc. | 7.44 Million USD | -91.065% |
| SYBLEU INC | 330.46 Thousand USD | -4203.291% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -657.29% |
| argenx SE | 4.54 Billion USD | 99.687% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 49.109% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 70.188% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -62324.828% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -58.909% |
| AVAX Technologies, Inc. | 7.37 Million USD | -92.771% |
| Zenith Capital Corp. | 7410.00 USD | -191816.329% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.58% |
| Ember Therapeutics, Inc. | 184.00 USD | -7728704.348% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -4319.122% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -5341.071% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 96.814% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -881.542% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -370.102% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 73.016% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1432.5% |
| BioStem Technologies, Inc. | 14.56 Million USD | 2.33% |
| ONE Bio Corp. | 70.08 Million USD | 79.709% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -24808.046% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -615527.706% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1339.421% |
| Agentix Corp. | 261.39 Thousand USD | -5340.488% |
| LadRx Corporation | 2.3 Million USD | -516.193% |
| Cell Source, Inc. | 195.17 Thousand USD | -7186.431% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2859.274% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3921.583% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3921.583% |
| NovAccess Global Inc. | 62.24 Thousand USD | -22745.714% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -2123.226% |
| Itoco Inc. | 1.4 Million USD | -915.733% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -14766.659% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -13316.038% |
| Kadimastem Ltd | 2.3 Million USD | -517.209% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -18525.088% |
| CytoDyn Inc. | 11.13 Million USD | -27.703% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -9846.703% |
| Mobile Lads Corp. | 52.00 USD | -27347976.923% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -79435.794% |
| Qrons Inc. | 420.00 USD | -3385852.381% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -3589.253% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2475.708% |
| Rebus Holdings, Inc. | 5000.00 USD | -284320.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -3373.433% |
| International Stem Cell Corporation | 5.39 Million USD | -163.84% |
| Bioxytran, Inc. | 137.63 Thousand USD | -10232.176% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 5.205% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 14.223% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -17901.266% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1544.66% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -89.185% |
| Neutra Corp. | 2851.00 USD | -498707.436% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 56.116% |
| PureTech Health plc | 693.97 Million USD | 97.951% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -76.197% |
| IXICO plc | 15.84 Million USD | 10.243% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -71.71% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 86.236% |
| CSL Limited | 38.02 Billion USD | 99.963% |
| Cellectis S.A. | 333.99 Million USD | 95.742% |